| abstract |
The present invention relates to the use of NK1 antagonists, in the treatment of depression. Also described are novel NK1 antagonists of formula (I), processes for their preparation, pharmaceutical compositions containing them and their medical use. The compounds of formula I are as follows: having a formula (I)whereinR represents the ring Aor2-pyridinyl or 2-pyridinyl-N-oxide;R1 is selected from the group consisting of halogen atoms, C1-4alkyl, C1-4alkoxy, trifluoromethyl, and S(O)nC1-4alkyl groups;R2 and R3, which may be the same or different, each independently are selected from the group consisting of hydrogen atoms, halogen atoms, C1-4alkyl, C1-4alkoxy, trifluoromethyl and cyano groupss;n represents zero, 1 or 2;and pharmaceutically acceptable salts and solvates thereof. |